Authors found that the 20-year cancer-specific mortality rate was 4.00% in ductal carcinoma in situ and 9.65% in DCIS-Mi (HR, 2.482; p < 0.001), highlighting that DCIS-Mi was associated with more aggressive biological parameters such as ER negative, PR negative, HER2 positive and lymph node metastasis (all p < 0.001) [71]. Here, ERBB2 is linked to ductal breast carcinoma in situ.